Studies on the inhibitory effect of isavuconazole on flumatinib metabolism in vitro and in vivo
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2023.1168852
Abstract: As the validated agent for the treatment of chronic myelogenous leukemia (CML), flumatinib is a novel oral tyrosine kinase inhibitor (TKI) with higher potency and selectivity for BCR-ABL1 kinase compared to imatinib. Many patients experience… read more here.
Keywords: vitro vivo; isavuconazole; flumatinib metabolism; liver microsomes ... See more keywords